Article Abstract

Bacille-Calmette-Guerin non-responders: how to manage

Authors: Friedrich-Carl von Rundstedt, Seth P. Lerner


Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is to describe the various disease states following induction and maintenance BCG and to describe contemporary treatment options and the current and projected clinical trial landscape for patients who recur following BCG therapy.